Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Clemson University scientists are working to determine how neurons are generated, which is vital to providing treatment for neurological disorders like Tuberous Sclerosis Complex (TSC).
TSC is a rare genetic disease that causes the growth of tumors in the brain and other vital organs and may indicate such disorders as autism, epilepsy and cognitive impairment that may arise from the abnormal generation of neurons.
"Current medicine is directed at inhibiting the mammalian target of rapamycin (mTOR), a common feature within these tumors that have abnormally high activity," said David M Feliciano, assistant professor of biological sciences. "However, current treatments have severe side effects, likely due to mTOR's many functions and playing an important role in cell survival, growth and migration."
Feliciano and colleagues published their findings in journal Cell Reports.
"Neural stem cells generate the primary communicating cells of the brain called neurons through the process of neurogenesis, yet how this is orchestrated is unknown," said Feliciano.
The stem cells lie at the core of brain development and repair, and alterations in the cells' self-renewal and differentiation can have major consequences for brain function at any stage of life, according to researchers.
To better understand the process of neurogenesis, the researchers used a genetic approach known as neonatal electroporation to deliver pieces of DNA into neural stem cells in young mice, which allowed them to express and control specific components of the mTOR pathway.
The researchers found that when they increase activity of the mTOR pathway, neural stem cells make neurons at the expense of making more stem cells. They also found that this phenomenon is linked to a specific mTOR target known as 4E-BP2, which regulates the production of proteins.
Ultimately, this study points to a possible new treatment, 4E-BP2, for neurodevelopmental disorders like TSC and may have fewer side effects.
Future experiments are aimed at identifying which proteins are synthesized due to this pathway in neurological disorders.
This material is based upon work supported by the National Institutes of Health under Grant No. 10668225 and the Connecticut Stem Cell Research Program. Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Institutes of Health.
mTORC1 Targets the Translational Repressor 4E-BP2, but Not S6 Kinase 1/2, to Regulate Neural Stem Cell Self-Renewal In Vivo. Nathaniel W. Hartman, Tiffany V. Lin, Longbo Zhang, Grace E. Paquelet, David M. Feliciano, Angélique Bordey. Cell Reports, 17 October 2013 10.1016/j.celrep.2013.09.017
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Neurology / Neuroscience category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Clemson University. "Study points to possible treatment for brain disorders." Medical News Today. MediLexicon, Intl., 24 Oct. 2013. Web.
10 Dec. 2013. <http://www.medicalnewstoday.com/releases/267812>
Clemson University. (2013, October 24). "Study points to possible treatment for brain disorders." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267812.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.